The study aims to understand the long term results of using Zenith Alpha thoracic stent-graft for aortic repairs.

It is a retrospective study on 44 consecutive subjects (25 male) with a minimum of five years follow-up in surviving subjects. The subjects underwent treatment in a center between 2010 and 2014. The stent-graft was the primary treatment for thoracic aortic aneurysms in 37 patients, penetrating aortic ulcer in 2, and thoracoabdominal aortic aneurysm in five. The study’s primary endpoint was five years after clinical success. The clinical success indicated freedom from secondary intervention, type I or III endoleak, aneurysm or procedure-related death, aneurysm expansion, infection, rupture, thrombosis, or conversion. The secondary endpoints were being free from all-cause mortality, stent fracture, device migration, endoleak, erosion of fabric, access vessel complication, and neurological events.

The clinical success rate was 84%, and four deaths due to aneurysm, type I or III endoleaks, and aneurysm expansion. 7% had access vessel complications, 5% had migration, and there were no fabric tears, stent fractures, or postoperative neurological problems.

Although the profile was restrictive, the Zenith Alpha thoracic stent-graft is efficient for long-term results. It is also favorable for multimorbid individuals, demanding iliac anatomy.